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ABSTRACT 
HIV persistent infection requires a life-long treatment and among the 2.1 million new 
HIV infections that occur every year there is an increased rate of transmitted drug-
resistant mutations. This fact requires a constant and timely effort in order to identify 
and develop new HIV inhibitors endowed with innovative mechanisms. The HIV-1 
Reverse Transcriptase (RT) associated Ribonuclease H (RNase H) is the only viral 
encoded enzymatic activity that still lacks an efficient inhibitor despite the fact that it 
is a well-validated target whose functional abrogation compromises viral infectivity. 
Identification of new drugs is a long and expensive process that can be speeded up by 
in silico methods. In the present study, a structure-guided screening is coupled with a 
similarity-based search on the Specs database to identify a new class of HIV-1 RNase 
H inhibitors. Out of 45 compounds selected for experimental testing, 15 of these 
inhibited the RNase H function below 100 µM with three hits possessing IC50 values 
<10 µM. The most active compound AA inhibits HIV-1 RNase H with an IC50 of 5.1 
µM, and possesses Mg-independent mode of inhibition. Site-directed mutagenesis 
studies provide valuable insight into the binding mode of newly identified 
compounds, for instance, compound AA involves extensive interactions with a 
lipophilic pocket formed by Ala502, Lys503, Trp (406, 426 and 535) and polar 
interactions with Arg557 and with the highly conserved RNase H primer-grip residue 
Asn474. The structural insights obtained from this work provide the bases for further 
lead optimization. 
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INTRODUCTION 
The increasing resistance to current therapeutic agents for HIV drug regiment remains 
a major issue for effective acquired immune deficiency syndrome (AIDS) therapy.1, 2 
It has recently been estimated (2016) that more than 36.7 million people are living 
with HIV, and among them only 18.2 million are on antiretroviral therapy and nearly 
1.1 million people died in 2015.1, 3, 4 Furthermore, 2.1 million new HIV infections 
occur every year. Although AIDS related mortality has been significantly reduced 
since the introduction of highly active antiretroviral therapy (HAART), (35% since 
2005), most of the currently marketed drugs that are being used today for HIV therapy 
are prone to viral resistance.5, 6 The number of newly infected people/year is constant 
and among them there is an overall increase of transmitted drug resistance mutations 
(TDRMs) detected in antiretroviral treatment–naive patients.2, 7 The resistance, which 
often results from lack of compliance, can relay to multiple types of drug, and can 
dramatically affect the outcome of HAART,8, 9 therefore, there is a strong need to 
search for non-traditional chemo-targets for anti-HIV drug developments.10-12 
Inhibition of the HIV-1 reverse transcriptase associated ribonuclease H (RNase H) 
function provides a novel target for anti-HIV chemotherapy, since it is the only viral 
encoded enzymatic function for which no inhibitor went in clinical development so 
far.13-15 Although it has been shown that inactivation of the RNase H function by 
amino acidic substitution lead to not infectious virions16 and its selective inhibition 
completely blocks viral replication.17, 18 
RNase H is one of the two catalytically active domains of the p66 subunit of HIV-1 
reverse transcriptase, which is essential for viral genome replication by performing 
the hydrolysis of the viral RNA strand in the RNA/DNA hybrid during the retro-
transcription process.19-22 In order to carry out the hydrolytic process, water molecules 
(act as nucleophiles) and magnesium ions (Mg2+) (initiate the deprotonation of water) 
coordinating with the highly conserved DDDE motif (Asp443, Asp498, Asp549 and 
Glu478) residues of RNase H are essential.23 The topology of the HIV-1 RNase H 
domain is well characterized from different studies.22, 24, 25 The active site is small and 
slightly hydrophobic and consists of a highly electronegative region, which is 
primarily due to the DDDE motif coordinated with the two catalytically active 
magnesium ions (Figure 1).22, 26 
In the past years, a large number of RNase H inhibitors have been reported but none 
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of these inhibitors have yet reached the market. 14, 15, 18, 20, 27-31 RNase H inhibitors can 
be classified into two categories based on the mode of action (i) compounds that 
block the magnesium ions availability to the hydrolytic process (the so called active-
site inhibitors), such as diketo,17, 32 N-hydroximide (e.g. NHQD, cf. Figure 1),33 
tropolone (e.g. β-thujaplicinol, cf. Figure 1), 34 pyrido-pyrimidinone, 30 N-hydroxy-
naphthyridinone, 35 thiocarbamates, 27 and 5-nitro-furan-2-carboxylic acid, 36 and (ii) 
allosteric inhibitors that impair the efficiency of the RNase H activity by binding 
outside the catalytic domain, inducing conformational changes that affect a proper 
substrate binding at the RNase H active site. This second class includes vinylogous 
ureas (e.g. NSC727447, cf. Figure 1), 37 acylhydrazones (e.g. BHMP07, cf. Figure 1), 
29, 38, 39 propenones, 25 isatines, 40 anthraquinones.41 Both classes of compounds 
present critical issues that hamper the process of drug-development. On the one hand 
Mg2+ coordination provides active-site inhibitors a strong and stable interaction with 
the catalytic domain, as shown for the last approved innovation for HIV-1 treatment, 
the integrase (IN) strand transfer inhibitors42, and as it has been proved for RNase H 
active site inhibitors RDS1759.17 However, both cases show that the Mg binding 
mechanism itself lacks specificity towards the other polynucleotidyl transferases (and 
indeed it is deeply investigated in order to look for IN and RNase H dual inhibitors 43-
45), and that the metal-binding moiety needs to be flanked by additional fragments 
able to specifically interact with the molecular environment in order to achieve 
sufficient potency and specificity.46 On the other hand, it has been proved that 
compounds that bind to allosteric non-conserved regions, as the non-nucleoside RT-
inhibitors, are more prone to selection of resistant strains.2 Therefore, in order to 
identify effective inhibitors with lower possibility of toxicity and drug resistance 
selection, there is a need to target also the most conserved peripheral regions of the 
HIV-1 RNase H domain, adjoining to allosteric pockets that are reported to differ in 
location in humans and viruses. 47, 48 
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Figure 1. The HIV-RT associated RNase H structural topology is shown with a 
bound ligand NHQD (green, ball and stick model). The catalytically important 
residues and magnesium ions (orange sphere) have been highlighted. 2D structures of 
representative molecules belong to the active site and allosteric RNase H inhibition. 
 
Recently, we proved that the lateral chains of prototype DKA inhibitors designed and 
synthesized by Costi et al.43, 44 arrange within the active site binding the highly 
conserved residues Asn474, Gln475 and Tyr501 of the HIV-1 RNase H.17  
These amino acids are part of the RNase H primer grip, so called because it 
extensively interacts with the DNA strain of the RNA/DNA heteroduplex, allowing 
the RNA to be in the right orientation to be cleaved by the active site. Mutations in 
the primer grip strongly impair viral replication49 by compromising RNase H 
specificity50 and efficiency.17 Compound BHMP07 (cf. Figure 1) binds to an allosteric 
pocket centered on Gln507 of p66 and composed of the residues Leu425, Leu422, and 
Asn404 residues, was also reported to interact with Asn474 (H-bond), Gln500 (H-
bond), Tyr501 (π-π stack), Asp498 (H-bond), Gly444 (H-bond) and Asp443 (H-bond) 
residues.47 This observation was further supported by a virtual enrichment study.48 
Therefore, highly conserved residues within the RNase H domain represent a 
promising target for development of efficient RNase H inhibitors, and this effort can 
be optimized using computer-aided drug design techniques.  
With the availability of a large number of high-resolution 3D crystal structures of 
drug target proteins, and deposits of a large number of ligand data in public databases, 
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both ligand and structure-guided in silico approaches are extensively utilized to 
identify new ligands with affinity for a wide range of protein targets.51-53 Recently, a 
ligand-based virtual screening (VS) strategy was used on HIV-1 RT for identification 
of dual inhibitors (polymerase and RNase H activity), 29 leading to identification of 
four compounds that inhibited the RNase H function in the low micromolar range, 
and the binding mode was further confirmed by a site-directed mutagenesis approach 
thus confirming the effectiveness of this method for identification of novel RNase H 
inhibitors. Along this line, we have developed various ligand- and structure-based 
virtual screening models such as machine learning methods, docking, shaped based 
evaluation, pharmacophore modeling and QM-based calculations.54, 55 From a 
structure-based docking approach, we found about 80-90 % of accuracy in terms of 
“enrichment” compared to other methods. In continuation, in the present study, we 
used virtual screening models from docking followed by shape-based methods to 
screen the Specs database (www.specs.net) to identify new chemotypes able to bind 
within the RNase H domain and inhibit the RNase H function. The best-ranked 
compounds from in silico screening have been selected for in vitro testing. Among the 
45 compounds screened for RNase H inhibition, three compounds were showed IC50 
values below 10 µM. In addition, the binding mode of these compounds has been 
investigated by site-directed mutagenesis and “induced-fit” molecular modeling 
obtaining insights for the further lead optimization. 
 
RESULTS AND DISCUSSION  
1. Structure-Based Virtual Screening 
We have previously shown that effective virtual screening of RNase H inhibitors from 
large chemical databases could be achieved using the combination of docking and 
QM-based refinement calculations.54, 55 In order to identify a novel chemo-type for 
RNase H inhibition and to validate previously developed computational methods, the 
best models were used to screen the Specs database (containing 277325 drug-like 
compounds for purchase) for HIV-1 RNase H inhibition screening (Figure 2). After 
application of general filters for ADMET property score and reactive groups, 343518 
molecules were docked within a computational model of the HIV-1 RT associated 
RNase H domain.22 A set of 1205 compounds was obtained at the end of the docking-
based virtual screening, and these compounds were subsequently used for QM-based 
refinement calculation based on density functional theory (DFT) calculations as 
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previously described 55 (Supporting information S1). The best-ranked 180 compounds 
from the screening were sorted for further inspection. To select a diverse set of 
structures for the biochemical assays, these compounds were clustered according to 
the structural similarity using the Canvas software from the Schrodinger suite.56 In 
total, 50 individual clusters were defined containing between 1 and 15 compounds 
and each cluster accounts for at least 75% structural similarity. In the next step, each 
individual cluster was visually inspected and the previously known compounds were 
removed from the hit list, which includes NSC727447, tropolone, pyrido-
pyrimidinone and tropolone scaffolds (The list of compounds used for clustering is 
provided in S2). At the end, 25 structurally diverse compounds, with the best scores 
(structures are provided in the S3) were chosen and purchased from the chemical 
vendor www.specs.net to be tested against the HIV RT-associated RNase H function 
in enzymatic assays.  
 
 
 
Figure 2. Overall workflow of structure-based virtual screening strategies applied.  
 
2. Inhibition of HIV-1 RT associated RNase H function 
The selected compounds were tested against HIV-1 RT associated RNase H function 
(Table 1). Out of 25 compounds tested (A-Y), 3 compounds inhibited the RNase H 
activity below an IC50 value of 100 µM and compound A showed an IC50 value of 
9.35 µM. Notably, none of these compounds has previously been reported as an 
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inhibitor for RNase H, however, compound A, share structural similarities to 
hydantoin molecules described as HIV RNase H inhibitors in the patent in 2005 (US 
20100063118) 57, and compound B shares very similar structural patterns with 
BHMP07 (cf. Figure 3). These interesting similarities confirm the robustness of the 
VS methods in identifying potential RNase H inhibitors. Interestingly, among the 
active compounds, compound C, that exhibited a modest IC50 value (61.25 µM), 
presents a scaffold that has never been reported before in relation to RNase H 
modulator (Figure 3). Thus, further investigation on this scaffold could be interesting. 
To find more similar compounds, which could potentially be used to understand the 
structure-activity relationship (SAR) for lead optimization, all three compounds A, B 
and C were used as query molecules for a similarity based further search. 
 
Figure 3. Initial hit molecules (A, B, C) from the first screening and compound “B” is 
highlighted regions where it shares common structural pattern as BHMP07. 
Compounds AQ, AR and as found as analogs of B and C by the shaped-based 
screening (see text for detail). 
Similarity based search and structure activity relationships (SAR) 
Similarity searches assume that molecules with similar physicochemical properties 
also have similar biological activity. This approach not only finds similar molecules 
or analogous but is also able to identify completely new chemo-types but having 
similar pharmacophoric points.58 In this study, a combination of shape or 
pharmacophore-based (vROCS) 59 and electrostatic-based similarity (EON)60 was 
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used on three active compounds (A, B and C) in the Specs database, identifying the 
20 best-scored compounds to be tested against the HIV RT-associated RNase H 
function in enzymatic assays. Among them 17 molecules were analogs of compound 
A with structures varying greatly in terms of length and also functional groups (Figure 
4). Two compounds BA and BB were found as analogs of B, and only one CA was 
found as an analogue of compound C (cf. Figure 3). 
Out of 20 hits, 12 compounds inhibited the RNase H function with IC50 values 
ranging from 5 to 91 µM (cf. Table 1, compound AA-AP). Interestingly, the better 
inhibitors were found among A analogs, with compound AA showing an IC50 value of 
5.17 µM. The A analogs showed indeed a great variety of structures in terms of length 
and also functional groups, however, there is a clear pattern in the scaffold among the 
tested compounds, as hydantoin-like molecules that all belongs to benzylidene 
hydantoins, a group less explored.57 Indeed, the structure of the compounds in the A 
series can be fragmented into three parts (moieties): a head (Part a), a linker (Part b) 
and a lipophilic group (Part c). Part a is either an imidazolidinedione or a 
thiazolidinedione moiety. In some cases one of the two carbonyl groups of the 
azolidindione ring can be replaced by a thiocarbonyl or an imino moiety (Figure 4).  
Part b consists of a more or less complex aromatic linker: aromatic or heteroaromatic 
ring substituted with hydroxyl, alkyloxy or amino groups, halogens or again aryl 
rings. If the linker is composed of the biaryl fragments, such as the case of 
compounds AB, AC, AD, AG, the compound exhibits stronger inhibition compared 
to shorter compounds AH-AO (the sole exception is AA discussed below).  
Part c significantly modulates the RNase H function and is mostly composed of 
groups such as arylhalides or nitroaryl or carbamoylphenyl groups. The approximate 
distance of part a, b and c is found to be 7.5 Å (benzylideneimidazolidinedione), 3.5 Å 
(linker), 4.5 Å (active region), respectively. Overall, the observation suggests that 
parts a, and b are essential for the activity, while part c greatly modulates the activity 
against the RNase H function, depending on the nature of the substituent: more 
lipophilic is the substituent more active is the inhibitor (compare derivatives AA, AB, 
AE with the less potent AG derivative). 
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Among the B analogues, the results obtained from the shape-based screening e.g., BA 
(IC50 = 36.43 µM) and BB (IC50 = >100 µM) (Table 1, cf. Figure 2), reveal that small 
changes in the structure leads to a large difference in inhibition e.g., compound B 
(IC50 = 49.9 µM) and BB. The major structural difference between these compounds 
lies in the presence of hydrogen bond donor e.g., hydroxyl or amino groups at the 
phenyl ring. Indeed, it has previously been shown that hydroxyl groups interact 
directly to the negatively charged residues at the active site.39 Moreover, the decrease 
of molecular density of the molecule (molecular density is molecular weight divided 
by vdw_vol (amu/Å3)) to an increasing inhibitory activity e.g. BHMP07 (0.795) > 
BA (0.817) > B (0.837) > BB (0.861) (the molecular density of each molecule is 
provided in the parenthesis). This observation is particularly interesting in relation to 
design of new compounds in this series. Finally, only one analog CA of compound C 
was unable to inhibit the RNase H function up to 100 µM concentration. 
Page 10 of 31MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
01
 F
eb
ru
ar
y 
20
18
. D
ow
nl
oa
de
d 
by
 U
pp
sa
la
 U
ni
ve
rs
ity
 o
n 
13
/0
2/
20
18
 0
8:
06
:5
8.
 
View Article Online
DOI: 10.1039/C7MD00600D
 11
 
Figure 4. Comparison of structure and activity of A analogs. 
Binding mode of inhibitors  
In order to acquire more information about the binding mode of the compounds a 
further investigation was performed with a particular focus on the four “hits” 
identified, A, AB, and AC comparing their binding mode with BHMP07 (an allosteric 
inhibitor) and N-hydroxy quinazolinedinone (a prototype inhibitor active binding the 
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active site) (NHQD, PDB ID: 3QIO). 22 Since there is no crystal structure with 
BHMP07 bound to the RNase H domain, we compared the docking pose of BHMP07 
from our docking methodology as previously reported. 39  
In the case of NHQD, for instance, His539 and Mg2+ interact with one of the three 
oxygen atoms of NHQD and the neighboring two oxygen atoms interact with the 
other Mg2+ (1) ion and bound water molecules (Figure 5, panel A). Differently, the 
binding pose of BHMP07 matched the previously determined binding pose, 39 as 
having hydrogen bonds with Asn474, Gln500, Asp498, Gly444, Asp433 and π-π 
stacking with Tyr501 (Figure 5, panel A).  
 
Figure 5. Comparison of the binding mode of known RNase H inhibitors, in a X-ray 
crystal, and important residues are highlighted. Panel A, N-hydroxy quinazolinedione 
inhibitor (NHQD, active site binder, green) and BHMP07 (allosteric site binder, 
cyan). Panel B, compound A (magenta), Panel C compound AA (blue), Panel D, 
compound AB (cyan). 
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For the imidazolidinedione scaffold, the head portion of all the inhibitors lies in close 
vicinity to negatively charged residues (Asp433 or Asp498) and interacts with 
Asn474. Moreover, a negatively charged nitrogen atom in the imidazolidinedione ring 
(e.g. compound A, panel B) is partially exposed to the magnesium ions and Arg557 as 
we have observed for the active site inhibitor NHQD.  Overall, the head portion of 
inhibitors is exposed or interacts with Arg557 (ionic or π interaction), the polar 
interactions are found either with Gly444, Asn474, Asp498, Gln500 or His539 
residues. The linker of the “hits” is primarily exposed to hydrophobic residues such as 
Ala502, Lys503, Trp (406, 426, 535) and Tyr501, thereby confirming that a linker 
composed as described above with one or two aromatic portions properly substituted, 
can provide additional interactions contributing to a stronger inhibition compared to 
the compounds that have substitution with halo-groups or ends in this region.  
The most important part of these hits is an “active region” fragment (preferably with 
arylhalides). Residues that lie in this region are more hydrophobic in nature e.g., 
Phe346, Trp406, Tyr406, Tyr405, Ala502 and Ile505. In addition, residues such as 
Gln507 and Pro421 also significantly interact with most active compounds. Some of 
these residues are located between the polymerase domain and RNase H domain of 
reverse transcriptase. 
Compounds in the same scaffold such as A and AA showed a slightly different 
binding mode compared to the rest of the compounds (Figure 5 panels B and C) since 
the negatively charged nitrophenol moiety of AA has high affinity towards the 
magnesium ions and this ionic interaction pulls the whole compound towards the 
active site. Since these ligands are small in size, the ionic interactions dominate the 
overall binding pose. Moreover, the hydrophobic residue Trp535 strongly interacts 
with the phenyl substituent at position 3 of the thioxothiazolidine of AA and with the 
pyrrolidine ring of A, respectively. The similar binding mode was observed for 
hydrazone derivatives AQ and B (Figure S3), in which favorable interactions of the 
inhibitors with Arg557 (ionic/π interaction), Gly444 (H-bonding) and Ala446 (H-
bonding) were found.  
3. Investigation of Magnesium-Complexation 
In order to investigate the potential importance for interaction between the active 
compounds and Mg2+ ions, spectrophotometric complexation studies were carried on 
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the selected compounds A, AA, AB, AC, AD, AE, AF and AG. Titration with MgCl2 
did not induce significant changes in the UV-Vis spectra of compounds AA, AC, AD, 
AE, AF and AG, thereby indicating a lack of interaction of these molecules with 
Mg2+ (Figures 6 panels A and C, and Supplementary material, S4 to S8) 
For compound A, we observed an overall increase in absorbance across the analyzed 
UV-Vis spectrum that could reasonably be attributed to an increase in the solubility 
due to the presence of magnesium ion rather than to a real complexation (Figure 6B). 
Differently, titration of compound AB with MgCl2 produced an increase of the 
absorbance at 282 and 392 nm (hyperchromic effect) with a slight shift towards 
higher wavelengths (hypsochromic effects); furthermore a disappearance of the 494 
nm maxima was observed. The titration spectra present two isosbestic points: the first 
at 407 nm appears at lower magnesium concentration, the second at 449 nm appears 
at higher magnesium concentration. This type of behavior suggests the presence of 
two subsequent complexation equilibria between AB and magnesium ions (Figure 
5D), supporting the hypothesis of the involvement of the interaction with the cofactor 
Mg2+ in the binding to the protein, and in agreement with the docking model. 
This finding is very interesting since it is the first time that the inhibition of 
metalloenzymes is reported for the phenol with flanking nitro and ethoxy group 
fragment. Compounds containing the nitrophenol fragment have been previously been 
investigated as inhibitors of HIV-1 integrase (IN)61, showing that the nitrophenol 
moiety is not sufficient to achieve inhibition of IN . Indeed this is in agreement with 
the much lower activity of compound B (IC50 = 49 µM) and BB (IC50 = >100 µM) 
that contain a similar nitrophenol moiety, but lack the ethoxy group, and are, therefore 
not able to coordinate the Mg as compound AB does. The phenol with flanking nitro 
and ethoxy groups fragment is structurally closely related to the more investigated 5-
nitrovanillin (CHEBI ID: 48385), that, on its side, has never been investigated for 
such property. Therefore, this finding could represent a new insight for the 
development of the AB scaffold. 
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Figure 6. Titration graph of inhibitor with Mg2+; Panel A:  compound AC, Panel B: 
compound A, Panel C: Compound AA and Panel D: compound AB. 
4. Site-directed mutagenesis  
In order to experimentally verify the binding model suggested by the computational 
studies, the most active compounds A, AA and AB were chosen to perform a site-
directed mutagenesis, determining the independent impact of several amino acid 
substitutions on the potency of the compounds to inhibit RNase H function.  First, we 
assessed the impact of the substitution of Asn474, a primer grip residue, with Ala. 
Then we attempted to reduce the space available for the binding of the “active region” 
fragment introducing a phenylalanine instead of Ala502. Moreover, we attempted to 
disrupt the interactions engaged by the head portion by mutating Arg557 into Ala. A 
further substitution, R448A, as previously identified specifically affecting the activity 
of DKA active site inhibitors17 was included as negative control. The active-site 
inhibitor β-thujaplicinol (BTP) 62 was used as a control (Figure 7 and Table 2). To 
understand the binding mode of the compounds used in the site-directed mutagenesis 
studies, molecular docking based on the “induced-fit” approach was utilized to 
mutated RT RNase H structure models.  
Page 15 of 31 MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
01
 F
eb
ru
ar
y 
20
18
. D
ow
nl
oa
de
d 
by
 U
pp
sa
la
 U
ni
ve
rs
ity
 o
n 
13
/0
2/
20
18
 0
8:
06
:5
8.
 
View Article Online
DOI: 10.1039/C7MD00600D
 16
 
Figure 7. The comparison of the binding mode of compounds A, AA, AB and BPT in 
the wild type and various clinically relevant mutants. 
 
Initially, the binding mode of BPT was investigated in four mutants (i.e. A502F, 
R557A, R4448A, N474A) and wild-type (WT). As shown in Table 2, there is no 
significant change in the IC50 of BPT in the mutants as compared to the WT. The 
“induced-fit” analysis also reveals that BPT possesses similar binding mode in all 
mutants compared to WT (cf. Supporting information, S9). BPT has shown to inhibit 
RNase H function through metal chelation. It is evident from the various binding 
poses that two of the three-hydroxyl groups strongly interact with one of the 
magnesium ions in the active site. We observe similar metal interaction pattern for 
compound AB (cf. Figure 4C) that was indeed the only one to show the isosbestic 
point and the shift proper to an actual Mg coordination. When assessed against the 
mutated enzymes, AB showed a lower impact of N474A substitution on its potency of 
inhibition when compared to the other compounds, a slight increase in IC50 when 
assessed against A502F and no significant effect of R557A substitution, proving that 
AB inhibits RNase H through metal chelation.  
Page 16 of 31MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
01
 F
eb
ru
ar
y 
20
18
. D
ow
nl
oa
de
d 
by
 U
pp
sa
la
 U
ni
ve
rs
ity
 o
n 
13
/0
2/
20
18
 0
8:
06
:5
8.
 
View Article Online
DOI: 10.1039/C7MD00600D
 17
 
Figure 8. The comparison of various binding modes of compound AA in the RNase 
H active site, wild type is shown in orange and N474A mutant shown in cyan. 
Important residues are highlighted.  
 
The other two compounds, AA and A, showed a similar behavior when tested against 
the mutated enzymes, with more pronounced variations in IC50 in the case of 
compound AA. Compound AA totally lost its potency of inhibition when assessed 
against N474A (>59 fold as compared to the WT) in accordance with the “induced-
fit” calculation that clearly shows the different binding interaction of AA in N474A-
substituted and WT RT (Figure 8). Although the binding mode looks quite similar in 
both cases, the binding pose in N474A is slightly shifted, leading to a significantly 
weakening of its key interactions with residues such as Ala538, Arg557, Asp549, 
Asp443, Asn474 and Ser499. Compound AA showed a significant loss in potency 
also in the case of A502F (5 fold) and R557A 2.5 fold, proving to have multiple and 
strong interactions within the RNase H domain, and, as expected, no change was seen 
for R448A. The overall results show that compound AA has a binding mode that 
differs significantly from the one reported for NHQD, 22 BHMP07, 35 and DKAs, 30 
providing interesting perspectives for the hit optimization.  
Furthermore, in order to confirm if the scaffolds are suitable of improvements without 
becoming toxic, and to check if they were able to inhibit HIV-1 replication in cell-
based assays, compounds A, AA, and AB were tested for cytotoxicity and inhibition 
of HIV-1 replication (data not shown). The results showed that compounds A, AA, 
and AB are not toxic up to 40 µM. Unfortunately, at the highest concentration tested 
they were not able to inhibit viral replication, however, the structural insights gained 
from the present work will drive the scaffolds improvements in order to reach the 
antiviral activity. 
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CONCLUSIONS 
In the effort to search for novel inhibitors of HIV-1 RT associated RNase H function 
we have identified 4 scaffolds A, AA, AB and AC that inhibited the RNase H 
function in the low micromolar range. Binding affinity studies, computational 
investigation of the binding modes, magnesium-complexation studies and a site-
directed mutagenesis revealed that the most active compound AA inhibit HIV-1 
RNase H with an IC50 of 5.1 µM, and showed a Mg-independent mode of action that 
involves multiple interactions within the RNase H domain, including the one with the 
highly conserved residue Asn474. The molecular determinants identified in this study 
of the binding mode will serve as a good starting point for further ongoing lead 
optimization. 
 
MATERIALS AND METHODS 
In silico screening protocol 
Specs compounds (www.specs.net) from the ZINC database63 were retrieved due to 
the fact that these compounds are commercially available for experimental screening. 
The purity of the final compounds (hits) used in the biochemical screening was 
verified by the chemical vendor using LC-MS and/or 1H NMR and showed at least 
95% purity. Out of 277.324 compounds, 1943 compounds were removed due to 
missing stereo chemical information using the KNIME workflow.64 The remaining, 
275.381 compounds were imported into the OMEGA (a 3D conformation generating 
tool) tool from the OpenEye software. 65 By default OMEGA reports multiple 
conformers for all compounds using the MMFF94S force field, however, in the 
present study only a single i.e., the lowest energy conformer was used.  
Compound preprocessing  
3D coordinates of all the compounds were imported into the Maestro module66 
available in the Schrödinger suite for further structural filtration and virtual screening 
process. The virtual screening (VS) workflow implemented in the Schrödinger suite 
was used. This includes ligand pre- and post-preparations 66-69 (e.g. generation of 
tautomers, minimization etc.), Lipinski filter, reactive group filters and docking 
workflow. In each step of the VS workflow, a significant reduction in the number of 
compounds was achieved. 67  
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Homology modeling and structure-based screening 
A computational model of the HIV-1 RT associated RNase H domain was built from 
an X-ray crystal structure (resolution of 1.4 Å) downloaded from the Protein Data 
Bank (PDB ID: 3QIO). 22 Missing residues were added using the Swiss-Model. 70 
Subsequently, the atomic coordinate of the protein was imported into the Maestro 
module66 implemented in Schrödinger Suite and the protein was further optimized 
(e.g., adding hydrogen atoms, assigning correct bond orders, building di-sulfide bonds 
and replacing crystal bound Mn2+ ions with catalytically active Mg2+ ions) using the 
Protein Preparation Wizard.69 The docking experiments were performed using the 
Glide module67 of the Schrödinger Suite as described in the previous section. Before 
the compound screening, the protein structure and the docking protocol were assessed 
by reproducing the bound conformation of ligands (3-hydroxy-6-
(phenylsulfonyl)quinazoline-2,4(1H,3H)-dione) by docking. 54 In this study, water 
molecules at the active site beyond 3 Å from the bound ligand were deleted. 
Shape-based similarity screening 
The rapid overlay of chemical structures (ROCS)59 and electrostatic (EON)60 
screening tools from the OpenEye 71 were used for shape and electrostatics based 
structural similarity searches. In both methods, the specs database is screened against 
the shape and electrostatic potential of a query molecule against a reference molecule. 
A detailed account of the theory behind these methods can be found elsewhere. 53 
Once the overlap is optimized, the shape or electrostatics similarity is computed using 
Tanimoto Combo (ranges 0-2, a high score indicates the higher shape and 
pharmacophore similarity).  
Structural clustering  
For compound clustering, a set of 166 MACCS structural keys was computed, 
subsequently, the hierarchical clustering was employed using the Tanimoto similarity 
(TS) as method of metric (TSAB =c/a+b-c, a= bits set to 1 in molecule A, b = bits set 
to 1 in molecule B, c = number of 1 bits common to molecule A and B).  
Binding affinity prediction 
Prediction of binding affinities for ligands in lead identification and optimization is a 
major challenge in computer-aided drug design. In this study, MM-GBSA was used to 
validate the binding mode of a series of ligands that binds to the protein. A detailed 
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account of the theory behind this method can be found elsewhere. 72, 73 To capture the 
“induced-fit” effect, protein-ligand complexes from docking experiments were further 
energy optimized using the Prime MM-GBSA with an implicit solvation model. 
During the optimization, both protein and ligands were treated as flexible for instance 
5Å region of the protein around the ligand was treated as flexible.  
HIV-DNA polymerase-independent RNase H activity determination 
HIV RT-associated RNase H activity was measured as described, 32 briefly in 100 µL 
reaction volume containing 50 mM Tris-HCl buffer pH 7.8, 6 mM MgCl2, 1 mM 
dithiothreitol (DTT), 80 mM KCl, 0.25 µM hybrid RNA/DNA 5'-
GAUCUGAGCCUGGGAGCU-Fluorescin-3' (HPLC, dry, QC: Mass Check) 
(available from Metabion) 5'-Dabcyl-AGCTCCCAGGCTCAGATC-3' (HPLC, dry, 
QC: Mass Check), increasing concentrations of inhibitor, whose dilution were made 
in water, and different amount of enzymes according to a linear range of dose-
response curve: 20 ng of WT RT, 37.5 ng R448A, 62.5 ng N474A; 100ng A502F; 75 
ng R557A. The reaction mixture was incubated for 1 h at 37 °C, stopped by addition 
of EDTA and products were measured with a multi-label counter plate reader Victor 3 
(Perkin Elmer model 1420-051) equipped with filters for 490/528 nm 
(excitation/emission wavelength). 
Site-directed Mutagenesis  
Amino acid substitutions were introduced into the p66 HIV-1 RT subunit of a HIV-1 
RT group M subtype B coded in a p6HRT-prot plasmid using the QuikChange 
mutagenesis kit by following the manufacturer’s instructions (Agilent Technologies 
Inc., Santa Clara, CA). Heterodimeric RT was expressed essentially and purified as 
described. 74 
Magnesium complexation study 
Complexation studies on were carried on the following compounds: AN-
648/41665045(A); AG-690/36550050 (AA); AG-690/36165052 (AB); AH-
487/15021157 (AC); AN-698/40677529 (AD); AN-698/40677530 (AE); AH-
487/40935633 (AF); AH-487/41035472(AG). The effects of the magnesium ions 
were evaluated by mean of spectrophotometric method, using a Perkin Elmer lambda 
40 UV-Vis spectrophotometer and Hellma quartz cuvette with 1cm optical path. 
Magnesium chloride 1M solution were purchased from Sigma-Aldrich (Milano, Italy) 
and was diluted with absolute ethanol to obtain 13 stock solutions ranging from 4 10-5 
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to 0.2 M.  Each studied compound was dissolved in 50-100 mL of absolute ethanol 
and the final concentration ranges between 3×10-5 and 8×10-5M; the obtained 
solutions were maintained 5 minutes in a ultrasonic bath. Each solution (3 mL) was 
placed in a cuvette and the UV-Vis spectra was recorded between 220 and 500 or 600 
nm using ethanol as reference. Thereafter, small volumes (10-15 µL) of the 
appropriate MgCl2 ethanolic stock solution were added both in the sample and in the 
reference cuvettes and the UV-Vis spectra were repeated; the Mg2+ concentration in 
the solutions was increased from 0 to 100-200 fold with respect to the studied 
compound, in about twenty consecutive increments. Each experiment was triplicate. 
Due to the scarce solubility of compound AH-487/40935633 (AF) in absolute ethanol 
was not possible to prepare a solution of known concentration; for this reason only 
three spectra were recorded, one in the absence and two in presence of a great excess 
of Mg2+. The titration graphs for the selected compounds are reported in the 
supplementary material. 
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Figure legends 
 
Figure 1. The topology of HIV-RT associated RNase H is shown with a bound ligand 
NHQD (green, ball and stick model). The catalytically important residues and 
magnesium ions (orange sphere) have been highlighted. 2D structures of 
representative molecules belong to the active site and allosteric RNase H inhibition. 
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Figure 2. Overall workflow of structure-based virtual screening strategies applied.  
 
Figure 3. Initial hit molecules (A, B, C) from the first screening and compound “B” is 
highlighted regions where it shares common structural pattern as BHMP07. 
Compounds AQ, AR and as found as analogs of B and C by the shaped-based 
screening (see text for detail). 
 
Figure 4. Comparison of structure and activity of A analogs. 
 
Figure 5. Comparison of the binding mode of known RNase H inhibitors, in a X-ray 
crystal, and important residues are highlighted. Panel A, N-hydroxy quinazolinedione 
inhibitor (NHQD, active site binder, green) and BHMP07 (allosteric site binder, 
cyan). Panel B, compound A (magenta), Panel C compound AA (blue), Panel D, 
compound AB (cyan). 
 
Figure 6. Titration graph of inhibitor with Mg2+; Panel A:  compound AC, Panel B: 
compound A, Panel C: Compound AA and Panel D: compound AB. 
 
Figure 7. The comparison of the binding mode of compounds A, AA, AB and BPT in 
the wild type and various clinically relevant mutants. 
 
Figure 8. The comparison of various binding modes of compound AA in the RNase 
H active site, wild type is shown in orange and N474A mutant shown in cyan. 
Important residues are highlighted.  
 
 
 
 
 
 
 
 
Table 1.  
In silico prediction scores and biological effects of VS hits on HIV-1 RT-associated 
RNase H activity  
 
ID  Vendor code Cluster Chelation# XP #  Mol Wt 
(Da)  
IC50 (µM) 
a 
A
1
 AN-648/41665045 36 -21.17 -7.68 317.34 9.35 ± 0.007 
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B
1
 AG-205/10367010  34 -51.14 -9.91 316.27 49.90 ± 9.7 
C
1
 AL-281/41935302 21 -42.49 -6.86 289.33 61.25 ± 2.7 
D
1
 AK-968/41922459 1 -11.03 -8.38 295.77 >100 (73.40) 
E
1
 AK-968/12713114 3 -34.61 -8.01 241.33 >100 (76.28) 
F
1
 AQ-099/42181915 4 -59.34 -8.57 286.10 >100 (84.45) 
G
1
 AP-853/43445377  8 -13.66 -9.67 275.29 >100 (82.70) 
H
1
 AF-399/07629003  10 -22.42 -9.18 228.21 >100 (89.07) 
I
1
 AE-848/08809049 11 -23.03 -7.36 369.17 >100 (69.14) 
J
1
 AN-648/41701113  11 -13.91 -6.86 348.38 >100 (77.90) 
K
1
 AQ-149/42447764 13 -87.78 -7.27 299.35 >100 (81.80) 
L
1
 AQ-149/43372378  13 -25.62 -7.19 319.40 >100 (77.55) 
M
1
 AK-968/41922490 27 -22.30 -8.13 190.24 >100 (83.52) 
N
1
 AI-204/31719028 28 -37.80 -8.45 237.28 >100 (76.50) 
O
1
 AJ-292/41685670 28 -35.68 -9.83 309.34 >100 (74.50) 
P
1
 AN-329/43248835 29 -54.79 -8.92 304.34 >100 (83.70) 
Q
1
 AO-080/42837941  30 -42.83 -9.65 305.37 >100 (86.00) 
R
1
 AK-968/41923774  42 -33.40 -9.04 322.34 >100 (80.00) 
S
1
 AO-433/42007915 49 -27.79 -7.54 371.43 >100 (80.41) 
T
1
 AF-399/41368457  45 -34.22 -9.34 335.36 >100 (80.00) 
U
1
 AG-205/32708023 31 -12.43 -7.79 359.34 >100 (59.43) 
V
1
 AG-690/33090008 39 -35.05 -7.49 313.35 >100 (87.24) 
W
1
 AK-968/41922494 43 -15.19 -9.05 340.14 >100 (94.56) 
X
1
 AK-968/40355672  26 -18.26 -8.15 236.31 >100 (70.44) 
Y
1
 AO-080/43441633 30 -35.71 -8.50 374.44 >100 (80.25) 
AA
2
 AG-690/36550050 36 - - 424.30 5.17 ±0.56 
AB
2
 AG-690/36165052 36 - - 402.45 12.82 ± 0.68 
AC
2
 AH-487/15021157 36 - - 456.33 8.73 ± 1.84  
AD
2
 AN-698/40677529 36 - - 315.37 12.30 ± 1.92 
AE
2
 AN-698/40677530  36 - - 331.83 16.06 ± 0.68 
AF
2
 AH-487/40935633 36 - - 591.09 17.78 ± 4.13 
AG
2
 AH-487/41035472 36 - - 331.37 19.31 ± 1.05 
AH
2
 AH-487/41457445 36 - - 367.36 28.11 ± 4.66 
AI
2
 AH-487/40935863 36 - - 260.29 52.80 ± 3.43 
AJ
2
 AN-988/14610013 36 - - 266.68 84.20 ± 15.50 
AK
2
 AH-487/41449196  36 - - 276.25 91.57 ± 11.92 
AL
2
 AN-698/40704420 36 - - 294.29 >100 (65.5) b 
AM
2
 AG-690/40144774  36 - - 265.29 >100 (60.0) b 
AN
2
 AH-487/40935550 36 - - 388.11 >100 (67.5) b 
AO
2
 AH-487/41449786 36 - - 296.71 >100 (70.0) b 
AP
2
 AG-690/40124767 36 - - 274.13 >100 (80.5) b 
AQ
2
 AK-968/41022607 36 - - 279.25 >100 (89.5) b 
BA
2
 AN-329/40081786  34 - - 297.27 36.43 ± 5.83 
BB
2
 AF-399/15030247 34 - - 321.32 >100 (55.0) b 
CA
2
 AK-968/15608063 21 - - 391.47 >100 (93.0) b 
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# Chelation and docking scores are in kcal mol-1 unit;  
a compound concentration required to reduce the HIV-1-RT associated RNase H 
activity by 50%; The table reports the average and standard deviation of three 
independent experiments. 
b Percentage of control activity in the presence of 100 µM concentration of compound;  
1First screening;  
2Secondary screening (Shape based search). 
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Table. 2  
Effect of selected compounds on HIV-1 RT associated RNase H function of mutated RTs 
  
  
A AA AB BTP 
IC50 (µM)
 a
 Foldb IC50 (µM)
 a
 Foldb IC50 (µM)
 a
 Foldb 
IC50 (µM)
 
a
 
Foldb 
Wild 9.35 ± 0.73 - 5.1 ± 1.89 - 12.82 ± 1.05 - 0.20± 0.02 - 
A502F 32.52 ± 2.83 3.5*** 26.72 ± 3.14 5.3*** 26.35 ± 1.01 2.1**** 0.17 ± 0.03 0.85 
R557A 20.54 ± 1.26 2.2*** 12.53 ± 1.36 2.5** 18.61 ± 0.42 1.5** 0.21 ± 0.05 1.05 
R448A 10.96 ± 1.12 1.20 7.01 ± 0.78 1.40 11.28 ± 0.64 0.9 0.14 ± 0.02 0.70 
N474A >300 >32**** >300 >59**** 146 ± 12 11.4**** 0.10 ± 0.01 0.50 
 
The table reports the average and standard deviation of three independent experiments. 
a Concentration required to inhibit HIV-1 RT-associated RNase H activity by 50% obtained by three independent experiments (reported as 
average ± standard deviation). p value < 0.05 (*); p value <0.01 (**); p value <0.001 (***); p value <0.0001(****). 
b Fold of increase with respect to wt RT. 
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